GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (NAS:MEIP) » Definitions » Shiller PE Ratio

MEI Pharma (MEI Pharma) Shiller PE Ratio : (As of May. 29, 2024)


View and export this data going back to 2003. Start your Free Trial

What is MEI Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MEI Pharma Shiller PE Ratio Historical Data

The historical data trend for MEI Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Shiller PE Ratio Chart

MEI Pharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MEI Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MEI Pharma's Shiller PE Ratio

For the Biotechnology subindustry, MEI Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MEI Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MEI Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where MEI Pharma's Shiller PE Ratio falls into.



MEI Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

MEI Pharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, MEI Pharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.37/131.7762*131.7762
=-1.370

Current CPI (Mar. 2024) = 131.7762.

MEI Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -8.000 100.560 -10.483
201409 -8.400 100.428 -11.022
201412 -7.800 99.070 -10.375
201503 -5.400 99.621 -7.143
201506 -2.600 100.684 -3.403
201509 -2.600 100.392 -3.413
201512 -3.000 99.792 -3.962
201603 -3.200 100.470 -4.197
201606 -3.400 101.688 -4.406
201609 -2.400 101.861 -3.105
201612 6.400 101.863 8.279
201703 -0.400 102.862 -0.512
201706 -2.400 103.349 -3.060
201709 -4.800 104.136 -6.074
201712 -3.200 104.011 -4.054
201803 -3.200 105.290 -4.005
201806 -8.200 106.317 -10.164
201809 -4.200 106.507 -5.196
201812 -3.000 105.998 -3.730
201903 -4.800 107.251 -5.898
201906 -3.000 108.070 -3.658
201909 -0.800 108.329 -0.973
201912 -5.200 108.420 -6.320
202003 -0.800 108.902 -0.968
202006 -4.000 108.767 -4.846
202009 -2.200 109.815 -2.640
202012 -2.600 109.897 -3.118
202103 -4.600 111.754 -5.424
202106 -2.600 114.631 -2.989
202109 -3.600 115.734 -4.099
202112 -2.800 117.630 -3.137
202203 -1.310 121.301 -1.423
202206 -2.440 125.017 -2.572
202209 -2.490 125.227 -2.620
202212 1.540 125.222 1.621
202303 -2.320 127.348 -2.401
202306 -1.510 128.729 -1.546
202309 8.460 129.860 8.585
202312 -1.660 129.419 -1.690
202403 -1.370 131.776 -1.370

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MEI Pharma  (NAS:MEIP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


MEI Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of MEI Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MEI Pharma (MEI Pharma) Business Description

Traded in Other Exchanges
Address
11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Executives
Taheer Datoo director 181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3
James P Flynn director 41 HARRIS CT, DANVILLE CA 94526
Sujay Kango director 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Richard G Ghalie officer: Chief Medical Officer C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Bruce Ross Winson 10 percent owner 5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225
Anson Funds Management Lp 10 percent owner 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Management Gp Llc 10 percent owner 16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Advisors Inc. 10 percent owner 155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7
Funicular Funds, Lp 10 percent owner 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Amin Nathoo 10 percent owner 155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7
Moez Kassam 10 percent owner 111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1
Justin J. File officer: CFO and Corporate Secretary C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Jacob Ma-weaver 10 percent owner 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Cable Car Capital Llc 10 percent owner 2261 MARKET STREET #4307, SAN FRANCISCO CA 94114
Baltic Charles V. Iii director C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130